Apricus Biosciences, Inc.
06.10.2011 15:52
---------------------------------------------------------------------------
SAN DIEGO, 2011-10-06 15:52 CEST (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio' or the 'Company') (Nasdaq:APRI)
(http://www.apricusbio.com) announced today that the submission of an abstract
entitled, 'Results of a Phase III Clinical Trial for Female Sexual Arousal
Disorder ('FSAD') with Femprox(r), a Topical Alprostadil 0.4% Cream with a Novel
Transdermal Delivery Technology,' was accepted as a moderated poster (#43) at
the upcoming Sexual Medicine Society of Northern America ('SMSNA') conference
in Las Vegas, scheduled to take place November 10-13, 2011.
Dr. Irwin Goldstein, a member of the Company's Femprox(r) Clinical Advisory
Board
and the Director of Sexual Medicine at the Alvarado Hospital in San Diego, will
present the poster with a short oral presentation and question and answer
session on Friday, Nov 11th during the Female Sexual Dysfunction session,
taking place from 4:15 pm to 5:45 pm PDT. Dr. Goldstein is an expert in the
field of women's sexual health, the Editor of The Journal of Sexual Medicine, a
member of numerous sexual medicine societies, and the author or co-author of
approximately 260 peer review papers, many in the area of women's sexual
health.
The poster presentation will discuss an age group analysis of a Phase III
clinical trial to provide further evidence of the statistically significant
efficacy and safety profile of Apricus' investigational drug, Femprox(r)
(topical
alprostadil 0.4 % cream), for the treatment of FSAD in pre- and post-menopausal
women.
About Femprox(r)
Femprox(r) is an alprostadil-based cream intended for the treatment of FSAD.
Apricus Bio has completed nine clinical studies to date, including one,
98-patient Phase II study in the U.S. and a 400-patient Phase III study in
China.
It is the Company's understanding that no product is currently approved for
FSAD in the U.S., a persistent or recurring inability to attain, or maintain
adequate sexual excitement, causing personal distress.
Femprox(r) exerts a local, relaxant effect on vulvar and clitoral blood vessels
in women, leading to increased blood flow. The resultant increase in
lubrication and sensory feedback is believed to produce a clinically
significant increase in sexual arousal in women with FSAD.
About Apricus Biosciences, Inc.
Apricus Bio, a San Diego-based, revenue-generating, biopharmaceutical company,
has leveraged the flexibility of its clinically-validated NexACT(r) drug
delivery
technology to enable multi-route administration of new and improved compounds
across numerous therapeutic classes.
Revenues and growth are driven from out-licensing of this technology for the
development and commercialization of such compounds to pharmaceutical and
biotechnology companies worldwide. In addition, the Company is seeking to
monetize its existing Rx Division product pipeline, including its first
product, Vitaros(r), approved in Canada for the treatment of erectile
dysfunction, which is currently expected to be available on the Canadian market
in 2011, as well as compounds in development from pre-clinical through Phase
III, currently focused on Sexual Dysfunction, Oncology, Dermatology,
Autoimmune, Pain, Anti-Infectives, Diabetes and Cosmeceuticals among others.
The Company is also developing its Consumer Healthcare Division by developing a
number of drugs that utilize the Company's NexACT(r) technology to comply with
the FDA's over-the-counter ('OTC') requirements, be cleared as 510(k) topical
creams that are considered to be medical devices or approved as Abbreviated New
Drug Applications ('ANDAs') as generic drugs. The Company will also seek to
market such drugs through these similar procedures in foreign countries.
For further information on Apricus Bio, visit http://www.apricusbio.com and for
information on its subsidiary, please visit www.nexmedusa.com. Information may
also be found at http://twitter.com/apricusbio, and
http://facebook.com/apricusbio.
Apricus Bio's Forward-Looking Statement Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with
the exception of the historical information contained in this release, the
matters described herein contain forward-looking statements that involve risks
and uncertainties that may individually or mutually impact the matters herein
described for a variety of reasons that are outside the control of the Company,
including, but not limited to, its ability to receive issued patents on its
NexACT(r) technology and products, develop such patented technology into product
candidates, have its Rx Division products and product candidates such as
Femprox(r) approved by relevant regulatory authorities and its Consumer
Healthcare Division products either approved or cleared by relevant regulatory
authorities or be in compliance with appropriate regulatory requirements, to
successfully manufacture and commercialize such Rx Division products along with
its Consumer Healthcare Division products and product candidates and to achieve
its other development, commercialization and financial goals. Readers are
cautioned not to place undue reliance on these forward-looking statements as
actual results could differ materially from the forward-looking statements
contained herein. Readers are urged to read the risk factors set forth in the
Company's most recent annual report on Form 10-K, subsequent quarterly reports
filed on Form 10-Q and other filings made with the SEC. Copies of these reports
are available from the SEC's website or without charge from the Company.
Apricus Biosciences, Inc.
Edward Cox, V.P.
Corporate Development & Investor Relations, Apricus Bio, Inc.
(858) 848-4249
ecox@apricusbio.com
Apricus Bio Investor Relations
Paula Schwartz
Rx Communications Group, LLC
(917) 322-2216
pschwartz@rxir.com
News Source: NASDAQ OMX
06.10.2011 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Apricus Biosciences, Inc.
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US9901429525
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
DGAP-News: Apricus Biosciences to Present Poster of Femprox(R) Phase III Clinical Data at Upcoming Industry Conference
| Source: EQS Group AG